Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Atmos Energy Corporation (ATO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Atmos Energy Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Atmos Energy Corporation trades at $177.96 (market cap $29.64B). The key difference: Atmos Energy Corporation is far larger — about 6.6× ACADIA Pharmaceuticals Inc.'s market cap, and Atmos Energy Corporation pays a 2.25% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | ATO | |
|---|---|---|
Market Cap | $4.49B | $29.64B |
Sector | Health | Utilities |
52-Week High | $28.06 | $192.25 |
52-Week Low | $20.06 | $151.99 |
Enterprise Value | $3.69B | $39.15B |
Dividend Yield | — | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
ATO trades at $177.58, up 0.4% today, with a bearish technical signal but neutral oscillators. Recent earnings beat expectations in Q1 2026, with revenue growth to $4.7B in 2025 and a net margin of 27.58%. The stock shows strong profitability and a P/E of 21.41, while analyst consensus is a Buy with a $188.86 target. A dividend of $1.00 was recently declared, supporting income appeal.
Outlook is positive due to earnings beats and defensive utility positioning, but risks include high capital expenditures and debt levels. Investment opportunity lies in steady growth and dividend consistency, though market volatility and interest rate sensitivity pose challenges for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →
